SEC Form 4

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

F

1. Name and Address Fowler Wyche	1 0	on*	2. Issuer Name and Ticker or Trading Symbol <u>ZIOPHARM ONCOLOGY INC</u> [ZIOP]		ionship of Reporting Pers all applicable) Director	ton(s) to Issuer 10% Owner				
(Last) 701 A STREET M	(First) NE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/26/2006		Officer (give title below)	Other (specify below)				
Street) WASHINGTON DC 20002 (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Code V		v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Common Stock, \$.001 par value								0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security 3. Transaction 3A. Deemed 5. Number 6. Date Exercisable and 7. Title and Amount 8. Price of Derivative 9. Number of 10. 11. Nature 2 of Securities Underlying Derivative Security (Instr. 3 and 4) Execution Date, Conversion Date derivative Transaction Expiration Date Ownership of Indirect (Month/Dav/Year) Derivative Security or Exercise Code (Instr. (Month/Dav/Year) Securities Form: Beneficial (Instr. 3) Price of (Month/Day/Year) 8) Securities (Instr. 5) Beneficially Direct (D) Ownership (Instr. 4) Derivative Acquired Owned or Indirect (A) or Disposed of (D) (Instr. 3, 4 and 5) Security Following (I) (Instr. 4) Reported Transaction(s) (Instr. 4) Amount or Number Expiration of Shares Date (D) Exercisable Date v (A) Title Code Director Common

Stock Option (right to buy)	\$4.31				(1)	12/22/2014	Stock, \$.001 par value	15,029		15,029	D	
Director Stock Option (riht to buy)	\$5.01	04/26/2006	A	15,000	04/26/2006	04/26/2016	Common Stock	15,000	\$0	15,000	D	
Explanation	n of Respon	ses:										

1. 7.515 shares vest on 12/22/05 and 7.514 shares vest on 12/22/06.

/s/ Wyche Fowler

04/27/2006

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.